

ONE-YEAR INTESTINAL ULTRASOUND IMPROVEMENTS IN UC PATIENTS ON BIOLOGIC OR JAKI THERAPY – INTERIM RESULTS OF THE TRUST BEYOND STUDY

Imma Fischer

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

Interim analysis of the TRUST BEYOND study in 77 ulcerative colitis patients shows that early transmural response at 12 weeks on intestinal ultrasound is associated with higher clinical remission rates at 52 weeks, suggesting predictive value for IUS monitoring in UC.

KEY POINTS

- At week 12, 67.5% of UC patients achieved transmural response ($\geq 25\%$ reduction or normalization of bowel wall thickness) and 31.2% achieved transmural healing (normalized bowel wall thickness and Doppler signal); at week 52, rates increased to 77.9% and 41.6%, respectively.
- Of patients with transmural response at week 12, 72.2% were in clinical remission at week 52 compared to 27.8% of those without early transmural response, though the difference was not statistically significant ($p = 0.178$).
- Patients with transmural response at weeks 12 and 52 had numerically lower SCCAI scores and reduced fecal calprotectin levels compared to those without transmural response.
- The study enrolled 77 UC patients (63.6% male, median age 38.6 years) with active disease (SCCAI 8.5 ± 2.2) receiving biologic or JAK-inhibitor therapy, with sigmoid colon most commonly affected (mean baseline bowel wall thickness 5.22 ± 1.28 mm).

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/9a2281c2-743b-11ee-b751-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.